The First and Only Non-Invasive Endometrial Receptivity Test
Introducing ORA™: The First and Only Non-Invasive Endometrial Receptivity Test
DISCOVER THE FUTURE OF pET
Gain in-depth insights into how ORA™ is revolutionizing endometrial receptivity testing. Download our detailed brochure and sample report and learn more about the benefits for your practice.
KEY FEATURES
Non-Invasive Testing
ORA™ utilizes a simple blood test, eliminating the need for uncomfortable biopsies.
Accuracy Assured
ORA™ offers clinicians a reliable tool, predicting the optimal implantation window in 95%+ cases.
Streamlined Process
Our Vault Storage Program simplifies sample storage, ensuring readiness for future analyses.
UNDERSTANDING ORA™
Clinicians, meet ORA™—the solution to endometrial receptivity testing’s traditional challenges. By analyzing microRNA biomarkers in patients’ blood, ORA™ provides accurate insights into endometrial status, eliminating the need for invasive procedures or mock cycles.
THE microRNA ADVANTAGE
Leveraging microRNA biomarkers, ORA™ offers a revolutionary approach to receptivity testing. These biomarkers reflect endometrial conditions, guiding clinical decisions with precision and confidence.
COMPARATIVE EXCELLENCE
Compared to traditional tests, ORA™ stands out with its stability and superior pregnancy rates. Clinicians can trust ORA™ for enhanced patient outcomes.
WHY CHOOSE ORA™?
Optimized Success Rates
ORA™ significantly boosts pregnancy success rates, exceeding 60% in clinical settings for patients with a history of implantation failure.
Optimized Success Rates
ORA™ significantly boosts pregnancy success rates, exceeding 60% in clinical settings for patients with a history of implantation failure.
Patient-Centric Care
By replacing biopsies with blood samples, ORA™ enhances patient comfort and compliance.
Clinical Versatility
In cases of inconclusive results, ORA™ allows for additional sampling to refine clinical decisions.
PATIENT SELECTION INSIGHTS
ORA™ empowers clinicians to tailor treatments for optimal outcomes, but it’s not right for every patient. Identify patients who benefit most from ORA™, particularly those with:
- A history of implantation failure
- Limited availability of high-quality embryos
- BMI variations
- Advanced maternal age (35+)
- Low AMH levels
INTEGRATING ORA™ INTO CLINICAL PRACTICE
Effortless Integration: Incorporate ORA™ seamlessly into treatment protocols, either through our Vault Program or traditional mock cycles. Clinical Guidance: Navigate sample submission with ease using our straightforward process guidelines.
INTRODUCING VAULT: PROACTIVE SAMPLE STORAGE FOR OPTIMIZED CARE
Empower your patient’s journey with VAULT—a proactive sample storage service designed exclusively for ORA™ users. Here’s how it works:
- Sample Collection: On the day of embryo transfer during the patient’s initial IVF treatment, simply collect a blood sample.
- Secure Storage: Entrust us with your sample, securely stored in our state-of-the-art facility for a nominal fee.
- Success or Analysis: If the IVF treatment succeeds, the sample can be safely disposed. In case of unsuccessful implantation, we analyze the sample to pinpoint the optimal implantation window for the next cycle.
- Time and Cost Savings: By eliminating the need for a mock cycle, VAULT accelerates the treatment process, optimizing resources and minimizing patient wait times.
Learn More About ORA™
Access our comprehensive brochure and sample report or connect with us directly for further information and support at info@intilabs.com
Explore Our Research
For a deeper understanding of the science behind ORA™, read our recently published manuscript in the International Journal of Molecular Sciences: Development of a Predictive Model for Optimization of Embryo Transfer Timing Using Blood-Based microRNA Expression Profile.
References
Chen, C. H., Lu, F., Yang, W. J., Yang, P. E., Chen, W. M., Kang, S. T., Huang, Y. S., Kao, Y. C., Feng, C. T., Chang, P. C., Wang, T., Hsieh, C. A., Lin, Y. C., Jen Huang, J. Y., & Wang, L. H. (2021). A novel platform for discovery of differentially expressed microRNAs in patients with repeated implantation failure. Fertility and sterility, 116(1), 181–188.
Chen M-J, Hsu A, Lin P-Y, Chen Y-L, Wu K-W, Chen K-C, Wang T, Yi Y-C, Kung H-F, Chang J-C, et al. Development of a Predictive Model for Optimization of Embryo Transfer Timing Using Blood-Based microRNA Expression Profile. International Journal of Molecular Sciences. 2024; 25(1):76.